Treatment of Mild to Moderate Facial Melasma With the Lumixyl Topical Brightening System
May 2012 | Volume 11 | Issue 5 | Case Report | 660 | Copyright © 2012
Background: Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl TM ) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the
associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma.
Objective: The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma.
Results: All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks.
Conclusions: Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma.
J Drugs Dermatol.2012;11(5):660-662.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Melasma is a common cutaneous disorder that presents as patches of darker pigmentation on the cheeks, forehead, upper-lip, nose, and chin.1 Melasma most commonly affects females of Asian and Hispanic descent and those with Fitzpatrick phototypes IV and higher.2 Moreover, pregnancy appears to be a contributing factor, supporting the proposed role of hormones in the regulation of melanogenesis in women.3,4 Various skin lightening agents such as kojic acid, azelaic acid, ascorbic acid (and its derivatives), and hydroquinone (and its arbutin derivatives) are currently used to treat melasma but are either efficacious and cytotoxic or mildly efficacious and non-toxic.5 Hence there remains a need for novel compounds with an improved therapeutic index.
It is well known that tyrosinase is the key enzyme that catalyzes the first two steps in the melanin synthetic pathway, making it a therapeutic target for regulating the overproduction of melanin in conditions such as melasma. The first author previously reported the in vitro tyrosinase-inhibiting properties of a novel oligopeptide (LumixylTM) as compared to that of hydroquinone.6 Results showed that the oligopeptide was 17-times more potent at inhibiting mushroom tyrosinase than hydroquinone. Moreover, it was shown that hydroquinone was highly cytotoxic to human melanocytes whereas the oligopeptide showed negligible cytotoxicity at all tested concentrations. We also previously reported the clinical efficacy of a 0.01% oligopeptide cream for treatment of recalcitrant facial melasma in Asian and Hispanic females with Fitzpatrick type IV skin that had previously failed 6 months of Tri-LumaTM.7 The aim of this case study is to report the synergistic efficacy of a 0.01% oligopeptide cream when used in combination with an antioxidant cleanser, 20% glycolic acid lotion, and a physical sunscreen (Lumixyl Topical Brightening System) for the treatment of mild-to-moderate facial melasma over 12 or 24 weeks.
All patients used the topical regimen over 12 or 24 weeks as follows: 1) antioxidant cleanser twice a day (am/pm) 2) 0.01% oligopeptide cream twice a day (am/pm), 3) 20% glycolic acid lotion every other day (am) for 2 weeks, then daily (am) for 2 weeks, then daily (am) and every other day (pm) for 2 weeks, followed by twice a day (am/pm) for 6 weeks (patient 4 used the lotion twice a day for 18 weeks), and 4) physical sunscreen every day (am). Standardized digital photography was used to document severity of melasma at baseline, and 6, 8, and 12 weeks. Digital photographs for patient patient 4 were taken at baseline and 24 weeks.